4 news items
Aligos Therapeutics Reports Recent Business Progress and First Quarter 2024 Financial Results
ALGS
7 May 24
multiple cohorts of untreated chronic hepatitis B (CHB) patients receiving once daily doses of ALG-000184 as monotherapy or in combination with entecavir
Aligos Therapeutics Presents Clinical Data At APASL 2024 From ALG-055009 And ALG-000184 Phase 1 Studies
ALGS
27 Mar 24
ALG-000184: Potential best-in-class small molecule CAM-E for chronic hepatitis B (CHB
Aligos Therapeutics Presents Positive Clinical Data at APASL 2024 from ALG-055009 and ALG-000184 Phase 1 Studies
ALGS
27 Mar 24
-000184: Potential best-in-class small molecule CAM-E for chronic hepatitis B (CHB) Oral Presentation
Aligos Therapeutics to Announce 4th Quarter 2023 Financial Results on March 12, 2024
ALGS
5 Mar 24
therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) and viruses with high unmet medical need such as chronic hepatitis B (CHB
- Prev
- 1
- Next